EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

JOONGANG DNM Co.Ltd (051980) fair value: what the stock is really worth

As of Sep 10, 2026: fair value of JOONGANG DNM Co.Ltd KRW 170, price KRW 1,035, upside -83.6%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7051980001

JD Thin data Sep 24, 2026

JOONGANG DNM Co.Ltd

051980 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 170.03 KRW · Strongly overvalued (−84%)
!Quality 31/100
!Weak Growth (revenue 5y +13.0 %/yr)
!Loss-making · -19.1% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (1/9)
!Narrow moat 13/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

15,160 KRW 392.00 KRW Fair Value 170.03 KRW Mar 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 392.00 KRW – 15,160 KRW · fair‑value band 116.53 KRW – 236.63 KRW · the 1,035 KRW price screens above the 170.03 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow JOONGANG DNM Co.Ltd in your weekly email

Every Wednesday you see whether JOONGANG DNM Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JOONGANG ADVANCED MATERIALS Co., Ltd. manufactures and sells communication equipment and video information display devices in South Korea and internationally.

Show more

JOONGANG ADVANCED MATERIALS Co., Ltd. manufactures and sells communication equipment and video information display devices in South Korea and internationally. The company engages in manufacture of PVC products and building materials chassis, door frames, ducts; distribution agency business; secondary battery materials business; window construction, electronic commerce, and mail order sales; wholesale, retail, franchise, and bakery business; LED and lighting systems; and interior design services. The company was formerly known as JOONGANG DNM Co.,Ltd and changed its name to JOONGANG ADVANCED MATERIALS Co., Ltd. in September 2023. JOONGANG ADVANCED MATERIALS Co., Ltd. was founded in 1999 and is headquartered in Anyang-si, South Korea.

Stock analysis

JOONGANG DNM Co.Ltd (051980) currently trades at 1,035 KRW, while our model-based Fair Value estimate is 170.03 KRW, implying the stock looks roughly 508.6% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 627.35 KRW per share, and 0 of the 7 models we run sit above the 1,035 KRW price.

Bear case: the DCF Models group reads lowest at 216.83 KRW, and 7 of the 7 models stay below the price. Evidence for this calculation is low.

Scenario range: 116.53 KRW (bear) to 236.63 KRW (bull), the price of 1,035 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

JOONGANG DNM Co.Ltd reported revenue of 19.8B KRW in FY2025 versus 13.0B KRW in FY2021, a compound +11.0%/yr. Reported net income was −5.5B KRW in FY2025.

Key figures

Market cap 115B KRW (≈ $84.3M) · P/S ratio 5.73 · Net margin −27.8% · Return on equity −3.6% · Return on assets (EBIT) −17.3% · Operating margin −99.6% · Revenue (TTM) 18.8B KRW · Revenue growth (YoY) −30.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 75% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −84%, 051980 screens richer than that median.

Fair Value models

Bear 116.53 KRW Fair Value 170.03 KRW Bull 236.63 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 166.33 KRW 221.34 KRW 314.49 KRW 78
Growth DCF 170.95 KRW 222.90 KRW 303.97 KRW 77
5Y Revenue Exit 139.65 KRW 216.83 KRW 329.49 KRW 70
All 7 models by family
DCF Models
FCF DCF 166.33 KRW 221.34 KRW 314.49 KRW 78
5Y Revenue Exit 139.65 KRW 216.83 KRW 329.49 KRW 70
10Y Revenue Exit 146.38 KRW 208.63 KRW 277.71 KRW 65
Multiples
EV/Revenue 131.91 KRW 219.71 KRW 307.52 KRW 52
Asset-Based
NCAV (Graham) 468.17 KRW 627.35 KRW 936.34 KRW 54
Growth DCF
Growth DCF 170.95 KRW 222.90 KRW 303.97 KRW 77
Rev-Margin DCF 139.65 KRW 222.39 KRW 327.82 KRW 70

Open the full fair value analysis →

Notify me when 051980 reaches fair value

Put 051980 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 31/100

Of which business quality 36 · Market factors (momentum, volatility) 13

Profitability 2
Margins and returns on capital today
Quality Growth 67
Are margins and returns improving?
Cashflow 62
Earnings quality: real cash, not paper profit
Fin. Strength 52
Balance sheet, leverage, solvency risk
Investment 28
Disciplined investing over empire-building
Low Volatility 28
Calm price path (market factor)
Momentum 8
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Start year 2020 (pandemic). Over 10 years: +0.5% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−99.8% (2020) → −22.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+40.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +37.4% a year for the price.

051980 screens 509% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare JOONGANG DNM Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −84% · Bottom 25%
Profitability
Return on assets −3% · Below median
Net margin (TTM) −19% · Bottom 25%
Operating margin (TTM) −100% · Bottom 25%
Growth and dividend
Revenue growth −30% · Bottom 25%
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/FCF 0.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 8
HEALTH (low debt)92 · sector 95
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $678.39 $686.04 +1%
Danaher Corporation DHR $223.77 $209.18 −7%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "JOONGANG DNM Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/051980

Frequently asked questions

Is JOONGANG DNM Co.Ltd (051980) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 170.03 KRW versus the last price from Sep 10, 2026 of 1,035 KRW, about −84% upside (overvalued).
What is the fair value of 051980?
Our model-based fair value for JOONGANG DNM Co.Ltd is 170.03 KRW (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 10, 2026): 1,035 KRW.
What is the quality score of 051980?
JOONGANG DNM Co.Ltd has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JOONGANG DNM Co.Ltd (051980)?
Our model-based price target is the fair value of 170.03 KRW (as of Sep 24, 2026) from 7 valuation models. Cautious scenario 116.53 KRW, optimistic scenario 236.63 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the JOONGANG DNM Co.Ltd stock forecast for 2026?
Our models put fair value at 170.03 KRW, about −84% upside versus the last price from Sep 10, 2026 of 1,035 KRW (overvalued). Cautious scenario 116.53 KRW, optimistic scenario 236.63 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of JOONGANG DNM Co.Ltd (051980)?
JOONGANG DNM Co.Ltd reported trailing-twelve-month revenue of about 18.8B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into JOONGANG DNM Co.Ltd (051980)?
For today's price to be fair in a discounted-cash-flow model, JOONGANG DNM Co.Ltd would have to grow free cash flow by +40.2 % per year for five years (discount rate 13.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 051980 use?
Our models discount JOONGANG DNM Co.Ltd at 13.4 %: a base by market capitalisation (micro), damped by beta 1.07, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For JOONGANG DNM Co.Ltd that is +40.2 % per year a year over ten years, using the same discount rate (13.4 %) and the same formula as our fair value.
How much growth has JOONGANG DNM Co.Ltd (051980) delivered so far?
Over the past 5 years revenue at JOONGANG DNM Co.Ltd grew +13.0 % a year. The price currently implies +40.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of JOONGANG DNM Co.Ltd (051980) growing?
The median revenue growth in the sector is +8.2 % a year. That is the yardstick for the growth priced into JOONGANG DNM Co.Ltd (+40.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of JOONGANG DNM Co.Ltd (051980)?
The free-cash-flow yield on the price is 2.18 %: that much free cash flow JOONGANG DNM Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of JOONGANG DNM Co.Ltd (051980)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JOONGANG DNM Co.Ltd it is 170.03 KRW per share (as of Sep 24, 2026), against a price of 1,035 KRW. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is JOONGANG DNM Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 051980 trades above its calculated fair value: price 1,035 KRW, fair value 170.03 KRW, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 051980?
No. The price is what the market pays today (1,035 KRW); the fair value is what the company's own numbers justify (170.03 KRW). For JOONGANG DNM Co.Ltd the two are 864.97 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is JOONGANG DNM Co.Ltd worth?
The market values JOONGANG DNM Co.Ltd at about 115B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 1,035 KRW; our models calculate a fair value of 170.03 KRW per share.
What do the bullish and bearish scenarios say about 051980?
Our models span a range for JOONGANG DNM Co.Ltd: cautious scenario 116.53 KRW, base 170.03 KRW, optimistic 236.63 KRW per share (as of Sep 24, 2026, price 1,035 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of JOONGANG DNM Co.Ltd (051980)?
Balance-sheet figures for JOONGANG DNM Co.Ltd (as of Sep 24, 2026): return on equity −3.6%, debt of 0.16 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 051980 from its 52-week high?
JOONGANG DNM Co.Ltd trades at 1,035 KRW, about 75% below its 52-week high of 4,125 KRW and 22% above the low of 845.00 KRW (as of Sep 10, 2026). Distance from the high says nothing about value: that is what the fair value of 170.03 KRW is for.
Which stocks are comparable to JOONGANG DNM Co.Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JOONGANG DNM Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 1,035 KRW, calculated fair value 170.03 KRW (−84%), Quality Score 31/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 051980 calculated?
We run JOONGANG DNM Co.Ltd through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 170.03 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. JOONGANG DNM Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JOONGANG DNM Co.Ltd (051980)?
The latest price we hold is from Sep 10, 2026 and stands at 1,035 KRW. Our model-based fair value is 170.03 KRW, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JOONGANG DNM Co.Ltd right now?
The price sits above even our optimistic bull case (236.63 KRW). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (116.53 KRW to 236.63 KRW) leaves room in how you read the outcome.

Key figures of JOONGANG DNM Co.Ltd

How large is the market capitalisation of JOONGANG DNM Co.Ltd (051980)?
The market capitalisation of JOONGANG DNM Co.Ltd is 115B KRW (≈ $84.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JOONGANG DNM Co.Ltd (051980)?
The price-to-sales ratio of JOONGANG DNM Co.Ltd is 5.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of JOONGANG DNM Co.Ltd (051980)?
The net margin of JOONGANG DNM Co.Ltd is −27.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JOONGANG DNM Co.Ltd (051980)?
The return on equity (ROE) of JOONGANG DNM Co.Ltd is −3.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JOONGANG DNM Co.Ltd (051980)?
On an EBIT basis the return on assets of JOONGANG DNM Co.Ltd is −17.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JOONGANG DNM Co.Ltd (051980)?
The operating margin of JOONGANG DNM Co.Ltd is −99.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JOONGANG DNM Co.Ltd (051980)?
Revenue at JOONGANG DNM Co.Ltd is growing −30.4% versus a year earlier (3y avg −12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at JOONGANG DNM Co.Ltd (051980)?
Earnings per share at JOONGANG DNM Co.Ltd are growing +282% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does JOONGANG DNM Co.Ltd (051980) carry?
The net debt of JOONGANG DNM Co.Ltd is 8.1B KRW (fiscal year 2025, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch JOONGANG DNM Co.Ltd in the live analysis

One click puts JOONGANG DNM Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.